Myriad Genetics expands SRL partnership in Japan to support future growth
Myriad Genetics has expanded its partnership with SRL, a leading clinical laboratory testing company in Japan, to enable local testing for its BRACAnalysis Diagnostic System. This collaboration aims to improve testing efficiency, shorten turnaround times for patients and clinicians by performing wet lab work locally, and establish a foundation for future precision medicine and companion diagnostic offerings in Japan. The move is expected to strengthen Myriad's position in its largest international market.
Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth
Myriad Genetics has expanded its collaboration with SRL in Japan to enable local BRACAnalysis Diagnostic System testing, pending regulatory approval. This partnership aims to improve testing efficiency and shorten turnaround times by eliminating the need to ship samples to Myriad's Utah lab. The company anticipates this local capability will support future precision medicine and companion diagnostic offerings in Japan, its largest international market.
Form SCHEDULE 13G/A MYRIAD GENETICS INC Filed by: Vestal Point Capital, LP
Vestal Point Capital, LP, and Ryan Wilder have filed an amended Schedule 13G/A for Myriad Genetics Inc. The filing indicates that neither Vestal Point Capital, LP, nor Ryan Wilder beneficially own any shares (0.00) of Myriad Genetics Inc.'s common stock as of the reporting date of September 30, 2026. This amendment updates previous ownership disclosures for the company, stating that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Myriad Genetics Data Breach Lawsuit Investigation
Shamis & Gentile P.A. is investigating a data breach at Myriad Genetics, Inc. that occurred on November 2, 2026. The biotechnology company detected unauthorized access to its IT network, leading to a potential exposure of sensitive personally identifiable information. Individuals affected by this breach may be entitled to compensation through a class action lawsuit.
Stephens & Co. maintains Myriad Genetics at Equal-Weight, raises price target to $6 from $3
Stephens & Co. has reiterated its "Equal-Weight" rating for Myriad Genetics (MYGN) and significantly increased its price target from $3 to $6, representing a 100% rise. This new price target suggests a potential upside of 4.9% from the stock's closing price of $5.72 on November 11. Investors can find more detailed analyst ratings and forecasts for Myriad Genetics on the Forecasts tab and track past and future recommendations in the News Flow section.
Myriad Genetics Data Breach Exposes Sensitive Patient Information
Myriad Genetics Inc., a biotechnology company specializing in genetic testing, has disclosed a data breach to the U.S. Securities and Exchange Commission on November 2, 2026. While specific details about the breach, including the method of attack and the timeline of unauthorized activity, remain limited, consumers who have used the company's services are advised to monitor official communications for important details regarding the types of personal or health information involved and available resources. The article highlights that the types of information affected, such as names, social security numbers, and medical data, have not yet been fully disclosed by Myriad Genetics.
Form 4 Myriad Genetics Inc: Jennifer Lynne Fox (Chief Legal & Corp Strategy) For: 6 November By Investing.com
This article reports on a Form 4 filing for Myriad Genetics Inc, detailing an insider transaction by Jennifer Lynne Fox, the Chief Legal & Corp Strategy. The transaction was dated for November 6. The article reiterates this information without providing further details about the nature of the transaction.
Retention options for three Myriad Genetics (MYGN) executives vest after three years, subject to service.
Myriad Genetics, Inc. (MYGN) approved one-time retention stock option awards for three executives on November 6, 2026, aimed at promoting leadership retention and continuity while the company improves operational efficiencies and financial performance. The awards for CFO Benjamin R. Wheeler (121,379 shares), COO Mark S. Verratti (146,933 shares), and CSO Dale Muzzey (92,632 shares) will vest and become exercisable on the third anniversary of the grant date, contingent on continued service. Each option's exercise price is set at the closing price of MYGN common stock on the grant date and has a 10-year term.
Q3 revenue slips to $202.7M as Myriad Genetics (MYGN) posts a wider net loss.
Myriad Genetics reported a Q3 2026 revenue of $202.7 million, a slight decrease from $205.7 million a year earlier, and a widened net loss of $43.9 million, compared to $27.4 million in Q3 2025. The company announced an agreement to sell its Prenatal Health business to Laboratory Corporation of America for $210 million in cash, aiming to use the proceeds for general corporate purposes, including debt repayment and investment in its Cancer Care Continuum business. For the first nine months of 2026, revenue was $593.8 million, with a net loss of $121.2 million.
Myriad Genetics Data Breach Investigation
Strauss Borrelli PLLC is investigating a reported data incident involving healthcare company Myriad Genetics, Inc. A public filing on November 2, 2026, indicated an incident but did not specify the date, how it occurred, or what information was compromised. Affected individuals are advised to review direct notices, monitor accounts, and consider legal options.
Myriad Genetics earnings beat by $0.09, revenue topped estimates
Myriad Genetics (NASDAQ: MYGN) reported stronger-than-expected first-quarter results, beating analyst estimates for both earnings per share and revenue. The company posted an EPS of $-0.11 against an estimated $-0.20, and revenue of $202.7M, surpassing the consensus of $191.33M. Despite the beat, the company provided full-year 2026 revenue guidance that fell short of analyst expectations.
Myriad Genetics reports unauthorized access to IT network, resumes most operations
Myriad Genetics detected unauthorized access to its IT network, leading to a temporary suspension of testing operations and order management systems. The company has since resumed most operations and does not believe the incident will have a material adverse effect on its business, though the full extent of the access, including potential patient data compromise, is still under investigation. This incident occurred amidst a recent decline in the company's stock, despite the company recently surpassing Q3 2026 financial expectations.
Myriad Genetics, Inc. Stock 12‑Month Price Target Raised to $5.22, Implies 13% Downside
Myriad Genetics, Inc. (MYGN) has seen its average 12-month price target raised from $4.49 to $5.22 by 8 analysts, with forecasts ranging from $2.5 to $8 per share. This updated target implies an approximately 13% potential downside based on the November 4 closing price. The consensus rating for the stock remains "Hold" among 9 analysts, with 1 Buy, 6 Holds, and 2 Sells.
Myriad Genetics Reports Unauthorized Network Access; Most Systems Restored
Myriad Genetics (MYGN) detected unauthorized access to its IT network, leading to a temporary suspension of testing operations and order management systems. While most systems have been restored, an investigation is ongoing to determine the scope of the access and whether patient records were compromised. The company does not currently anticipate a material adverse business effect.
Myriad Genetics reports unauthorized access to IT network, resumes most operations
Myriad Genetics (NASDAQ:MYGN) disclosed unauthorized access to its IT network, leading to a temporary suspension of operations and system credential resets. The company is investigating the incident, including potential patient record access, but does not anticipate a material adverse effect on its business. This news follows a recent stock decline and strong Q3 2026 financial results that surpassed analyst expectations.
Myriad Genetics (MYGN) shares skyrocket, what you need to know
Shares of Myriad Genetics (MYGN) surged 8.1% after the company reported its third-quarter 2026 financial results, which included revenue of $202.7 million. Myriad Genetics also raised its full-year 2026 revenue guidance and finalized an agreement to sell its Prenatal Health business to Labcorp for $210 million in cash. This divestiture is expected to contribute approximately $160 million in revenue for Labcorp in its first year, with the deal projected to close by early 2027.
Form 8K Myriad Genetics Inc For: 5 November By Investing.com
This article from Investing.com announces that Myriad Genetics Inc. filed a Form 8K on November 5. The filing is a standard procedure for companies to announce significant events or disclose material information to shareholders and the public. The brief report highlights Myriad Genetics' stock performance, showing a 4.49% increase.
Myriad Genetics Q3 Earnings Call Highlights
Myriad Genetics reported Q3 revenue of $202.7 million, a 1% decrease year-over-year, despite growth in cancer and mental health testing being offset by a decline in its prenatal business. The company is selling its prenatal health business to Labcorp for $210 million to refocus on cancer testing and improve its financial profile. Myriad also raised its full-year revenue outlook and anticipates meaningful progress toward profitability in 2027, while addressing reimbursement challenges in its hereditary cancer testing.
Myriad Genetics Q3 2026 Earnings Call Transcript
Myriad Genetics reported Q3 2026 revenue of $202.7 million, driven by growth in cancer care and mental health tests, despite a decline in prenatal health test volume. The company announced the divestiture of its prenatal health business to LabCorp for $210 million to focus on the cancer care continuum and improve financial stability. Guidance for full-year 2026 revenue was raised to $780-790 million, reflecting strong performance and expected improvements post-divestiture.
Labcorp agreed to buy Myriad's prenatal testing business for $210 million in cash, plus inventory value.
Myriad Genetics (MYGN) announced it will sell its Prenatal Health business to Labcorp for $210 million in cash, plus inventory value, with the transaction expected to close by early 2027. The company reported third-quarter 2026 revenue of $202.7 million and a net loss of $43.9 million, raising its full-year 2026 revenue guidance to $780-$790 million to reflect the sale and current business trends. This divestiture is part of Myriad's strategy to focus on its Cancer Care Continuum and Mental Health businesses, which showed growth in test volumes and revenue.
Myriad Genetics Raises Lower End of Full-Year 2026 Guidance as Q3 Revenue Slides 1 Percent
Myriad Genetics reported a 1 percent decline in its third-quarter revenue for 2026. Despite this decrease, the company has raised the lower end of its full-year 2026 guidance, as announced by a staff reporter on November 04, 2026.
Myriad Genetics (NASDAQ:MYGN) reports upbeat Q3 2026, stock jumps 10.7%
Myriad Genetics (NASDAQ:MYGN) reported better-than-expected Q3 2026 results, with revenue beating Wall Street estimates despite a 1.5% year-on-year decline, and adjusted EPS significantly surpassing consensus. The company raised its full-year revenue guidance and announced the sale of its Prenatal Health business to focus on Cancer Care Continuum, leading to a 10.7% jump in its stock price. Despite the positive quarter, concerns remain regarding its historical revenue growth, consistent lack of profits, and declining adjusted operating margin.
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, a leader in molecular diagnostic testing, announced its participation in three upcoming healthcare conferences: the UBS Global Healthcare Conference on November 10, 2026, the 2026 Stephens Investment Conference on November 18, 2026, and the 38th Annual Piper Sandler Healthcare Conference on December 2, 2026. Management will host fireside chats at each event, with live audio webcasts available on the company's investor website.
Form 4 Myriad Genetics Inc: Jennifer Lynne Fox (Chief Legal & Corp Strategy) For: 1 November By Investing.com
This article reports on a Form 4 filing for Myriad Genetics Inc, detailing a transaction by Jennifer Lynne Fox, the company's Chief Legal & Corporate Strategy officer, on November 1st. The filing provides information about insider trading activity for the company.
A 39,370-unit stock grant at Myriad Genetics (MYGN) vests in three equal annual installments.
Myriad Genetics Inc. (MYGN) granted its Chief Legal & Corp Strategy officer, Jennifer Lynne Fox, 39,370 time-based restricted stock units on November 1, 2026. These units, part of the 2026 Employee, Director and Consultant Equity Incentive Plan, will vest in three equal annual installments beginning on the first anniversary of the grant date. Following this award, Fox's direct holdings increased to 345,334 shares of common stock.
Earnings to watch: Myriad Genetics (MYGN) reports Q3 results tomorrow
Myriad Genetics (MYGN) is set to announce its Q3 earnings, with analysts expecting a 7.1% year-on-year revenue decline after the company missed expectations last quarter. Despite past misses and declining revenue, investor sentiment in the therapeutics segment is positive, and Myriad Genetics' shares have risen by 29.5% over the last month. The company's average analyst price target is $4.49, against a current share price of $5.93.
Three healthcare conference talks are scheduled for Myriad executives
Myriad Genetics (MYGN) announced that its management will participate in fireside chats at three upcoming healthcare investor conferences: UBS Global Healthcare on November 10, 2026, Stephens Investment on November 18, 2026, and Piper Sandler Healthcare on December 2, 2026. Live audio webcasts of these presentations will be available on the company's investor relations website. The molecular diagnostic and precision medicine company aims to share insights on its advancements in health and well-being.
Form 4 Myriad Genetics Inc: Brian J. Donnelly (Chief Commercial Officer) For: 16 September By Investing.com
The article reports on a Form 4 filing for Myriad Genetics Inc, specifically detailing a transaction involving Brian J. Donnelly, the Chief Commercial Officer, for September 16. It originates from Investing.com and is categorized under stock market news.
Form 4 Myriad Genetics Inc: Brian J. Donnelly (Chief Commercial Officer) For: 16 September
This article reports on a Form 4 filing for Myriad Genetics Inc, specifically detailing an insider transaction involving Brian J. Donnelly, the Chief Commercial Officer. The filing is dated for September 16. The article reiterates this information multiple times and mentions the company's stock symbol, MYGN, which was down 6.46% at the time of publication.
Myriad Sued for Allegedly Misclassifying Patient’s Gene Variant
Myriad Genetics is facing a lawsuit for allegedly misclassifying a patient's gene variant. The article, published on October 30, 2026, highlights legal action taken against the genetics company for its diagnostic practices.
Myriad Genetics stock trades at EUR 5.97 in late L&S snapshot
Myriad Genetics stock was quoted at EUR 5.97 by Lang & Schwarz on October 29, 2026, at 10:59:30 p.m. Berlin time, showing no change from its previous close. This snapshot provides a late-session reference for the US-listed molecular diagnostics company, which develops and commercializes molecular tests for genetic insights. The company operates in the health care and life sciences sector, with medical equipment and supplies as its industry.
BlackRock reports sole voting power over 7.27M Myriad Genetics (MYGN) shares.
BlackRock Portfolio Management LLC has reported an 8.6% stake in Myriad Genetics Inc. (MYGN), beneficially owning 8,219,061 shares as of September 30, 2026. The filing indicates BlackRock holds sole voting power over 7,270,669 shares and sole dispositive power over 8,219,061 shares. This amended ownership report, a SCHEDULE 13G/A filing, details the investment firm's significant passive holding in the genetic testing company.
BlackRock Portfolio Management Discloses 8.6% Stake in Myriad Genetics Inc
BlackRock Portfolio Management LLC has disclosed an 8.6% beneficial ownership stake in Myriad Genetics Inc, amounting to 8,219,061 shares of common stock as of September 30, 2026. This information was revealed in an amended Schedule 13G filed with the SEC on October 27, 2026. The filing indicates BlackRock holds sole voting authority over 7,270,669 shares and sole dispositive authority over all 8,219,061 shares, with no shared voting or dispositive power reported.
Myriad Genetics Has Doubled Since Its Guidance Cut; Now Payer Pricing Must Stop Sliding
Myriad Genetics experienced a significant stock rebound despite cutting its full-year revenue outlook and suspending EBITDA guidance, doubling its value since the announcement. Investors are now focused on its upcoming Q3 results to determine if this rally reflects a genuine stabilization in reimbursement or merely relief that the worst news is out. The key challenge remains the decline in average revenue per test, as payer pricing must stabilize for volume growth to translate into profitability.
Weekly Recap: Myriad prenatal business acquisition and BioReference asset buy
Labcorp Holdings Inc. (LH) is expanding its diagnostics business by acquiring Myriad Genetics' prenatal testing business and select BioReference Health assets from OPKO, both moves expected to be accretive. Additionally, Labcorp declared a quarterly dividend of $0.72 per share. The acquisitions are part of Labcorp's strategy to strengthen its position in the diagnostics sector.
Myriad Genetics probe expands after 47% stock plunge and guidance cut
Following a 47% stock plunge and a significant cut in full-year guidance, Myriad Genetics (NASDAQ: MYGN) is facing expanded investigations by multiple law firms for potential securities fraud. The company's Q2 revenue fell 11% year-over-year, missing consensus estimates, and its full-year 2026 revenue guidance was slashed by $90 million due to reimbursement pressure, collection issues, and lower average revenue per test. Shareholders who purchased Myriad securities during the relevant periods are encouraged to contact the investigating law firms to discuss their rights.
Myriad Genetics, Inc. Estimates – NASDAQ:MYGN
This article provides an overview of Myriad Genetics, Inc. (NASDAQ:MYGN) financials and analyst estimates available on TradingView. It allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates. The platform also visualizes trends over time, providing tools for financial analysis.
Labcorp to buy Myriad’s prenatal health testing unit for $210M
Labcorp has announced its agreement to acquire Myriad Genetics’ prenatal health testing business for $210 million, a move expected to add approximately $160 million in revenue in its first year. This acquisition will expand Labcorp’s specialty testing portfolio for women’s health, incorporating tests like FirstGene, Prequel, Foresight, and SneakPeek. Analysts believe Labcorp can leverage its infrastructure and provider relationships to significantly improve the commercial performance and adjusted operating margins of the acquired business.
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Myriad Genetics announced new data from its MONSTAR-SCREEN-3 study, showcasing the potential of its Precise MRD™ platform for ultra-sensitive molecular residual disease (MRD) detection in resectable colorectal and pancreatic cancers. The whole-genome sequencing-based approach aims to identify recurrence risk earlier and provide more informed treatment decisions post-surgery. These findings will be presented at the European Society for Medical Oncology (ESMO) Congress 2026.
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history
Myriad Genetics, Inc. (MYGN) stock recently surged by 36.58% to $5.75 after announcing a definitive agreement to sell its prenatal health testing business to Labcorp for $210 million. The company, which specializes in molecular diagnostics and precision medicine, develops various tests for oncology, women's health, and pharmacogenomics. Myriad Genetics is headquartered in Salt Lake City, Utah, and is set to release its third-quarter 2026 financial results on November 4, 2026.
Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business
Myriad Genetics (NASDAQ: MYGN) stock surged nearly 37% after the company announced an agreement to sell its Prenatal Health testing business to Labcorp for $210 million in cash, plus inventory value. This strategic move aims to sharpen Myriad's portfolio, enhance profitability, and strengthen its balance sheet for investments in cancer care. Labcorp expects the acquisition to add approximately $160 million in revenue in the first year and be slightly accretive to adjusted earnings.
Current ratio of Myriad Genetics, Inc. – XETR:MYD
This article briefly presents financial data for Myriad Genetics, Inc. (XETR:MYD), specifically focusing on its current ratio. The content is sparse, indicating the current ratio's period, value, and change, but without providing the actual figures. The article appears to be a stub or a placeholder for more detailed financial information.
Myriad Genetics stock surges on $210M prenatal unit sale
Myriad Genetics Inc. (NASDAQ:MYGN) shares surged 36% after announcing the sale of its Prenatal Health testing business to Labcorp Holdings Inc. (NYSE:LH) for $210 million in cash. This transaction, expected to close by early 2027, aims to enhance Myriad's revenue growth and profitability while strengthening its balance sheet for investments in cancer care. Labcorp anticipates the acquisition will add approximately $160 million in revenue in the first year and be slightly accretive to adjusted earnings.
Form 8K Myriad Genetics Inc For: 20 October By Investing.com
This article announces that Myriad Genetics Inc. filed a Form 8K on October 20, 2026. The filing is an important regulatory disclosure for investors and the broader market. The stock symbol associated with Myriad Genetics is MYGN, which showed a gain of 1.04% at the time of publication.
Myriad to sell prenatal health business to Labcorp (MYGN:NASDAQ)
Myriad Genetics has agreed to sell its Prenatal Health testing business to Labcorp for an all-cash deal exceeding $210 million. This announcement led to a more than 20% surge in Myriad's premarket shares. The transaction marks a significant move for the molecular diagnostics firm.
MYGN Stock Draws Bullish Targets As Oncology Pivot Accelerates
Myriad Genetics Inc. (MYGN) stock surged over 23% following positive news regarding its genetic testing advancements and an oncology pivot. Analysts like Craig-Hallum and TD Cowen issued bullish targets, citing strong Q3 execution, FY26 guidance, and strategic collaborations in prostate cancer diagnostics. The company's Q3 2026 earnings call on November 4, 2026, will be a critical event for traders seeking confirmation of growth, margin improvements, and portfolio reshaping.
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Myriad Genetics has agreed to sell its Prenatal Health testing business, which includes tests like Prequel, Foresight, SneakPeek, and FirstGene, to Labcorp for $210 million in cash plus inventory value. This divestiture aligns with Myriad's strategy to focus on cancer care, aiming to enhance profitability and strengthen its balance sheet. Labcorp anticipates the acquisition will add approximately $160 million in revenue in the first year and expand access to its comprehensive laboratory services for patients and physicians.
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
Myriad Genetics (MYGN) shares jumped 22.2% in pre-market trading after the company announced the sale of its Prenatal Health testing business to Labcorp for $210 million in cash. This divestiture is expected to be accretive to Myriad's revenue growth and profitability, addressing a segment that had previously been a financial headwind. Despite the recent surge, Myriad Genetics stock is down 9.7% year-to-date and significantly below its 52-week high.
Myriad to Sell Prenatal Testing Business to Labcorp for $210M
Myriad Genetics has announced an agreement to sell its prenatal testing business to Labcorp for $210 million. The transaction was reported by a staff reporter on October 20, 2026, at 10:13 AM EDT. This move is part of Myriad's strategic adjustments in its business operations.
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Myriad Genetics has agreed to sell its Prenatal Health testing business, including tests like Prequel and SneakPeek, to Labcorp for $210 million in cash plus inventory value. Myriad expects the transaction to boost revenue growth and profitability while strengthening its balance sheet to support investments in cancer care. Labcorp anticipates the deal will add approximately $160 million in revenue in the first year and enhance its specialty testing growth strategy and women's health portfolio.